v3.26.1
Condensed Consolidated Statement of Stockholders’ Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2024   14,854,725    
Beginning balance at Dec. 31, 2024 $ 310,375 $ 0 $ 572,673 $ (262,298)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock-based compensation expense 4,048   4,048  
Common stock issued upon exercise of stock options (in shares)   1,683    
Common stock issued upon exercise of stock options 19   19  
Common stock issued upon vesting of restricted stock units (in shares)   73,158    
Net loss (22,647)     (22,647)
Ending balance (in shares) at Mar. 31, 2025   14,929,566    
Ending balance at Mar. 31, 2025 291,795 $ 0 576,740 (284,945)
Beginning balance (in shares) at Dec. 31, 2024   14,854,725    
Beginning balance at Dec. 31, 2024 310,375 $ 0 572,673 (262,298)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net loss (44,663)      
Ending balance (in shares) at Jun. 30, 2025   14,269,264    
Ending balance at Jun. 30, 2025 273,255 $ 0 580,216 (306,961)
Beginning balance (in shares) at Mar. 31, 2025   14,929,566    
Beginning balance at Mar. 31, 2025 291,795 $ 0 576,740 (284,945)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock-based compensation expense 3,408   3,408  
Common stock issued upon exercise of stock options (in shares)   7,198    
Common stock issued upon exercise of stock options 68   68  
Exchange of common stock for pre-funded warrants (in shares)   (667,500)    
Net loss (22,016)     (22,016)
Ending balance (in shares) at Jun. 30, 2025   14,269,264    
Ending balance at Jun. 30, 2025 $ 273,255 $ 0 580,216 (306,961)
Beginning balance (in shares) at Dec. 31, 2025 15,489,800 15,489,800    
Beginning balance at Dec. 31, 2025 $ 264,887 $ 0 617,536 (352,649)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock-based compensation expense 3,629   3,629  
Common stock issued upon exercise of stock options (in shares)   21,324    
Common stock issued upon exercise of stock options 201   201  
Common stock issued upon vesting of restricted stock units (in shares)   104,662    
Net loss (30,934)     (30,934)
Ending balance (in shares) at Mar. 31, 2026   15,615,786    
Ending balance at Mar. 31, 2026 $ 237,783 $ 0 621,366 (383,583)
Beginning balance (in shares) at Dec. 31, 2025 15,489,800 15,489,800    
Beginning balance at Dec. 31, 2025 $ 264,887 $ 0 617,536 (352,649)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Common stock issued upon exercise of stock options (in shares) 22,698      
Net loss $ (65,422)      
Ending balance (in shares) at Jun. 30, 2026 15,830,504 15,830,504    
Ending balance at Jun. 30, 2026 $ 217,133 $ 0 635,204 (418,071)
Beginning balance (in shares) at Mar. 31, 2026   15,615,786    
Beginning balance at Mar. 31, 2026 237,783 $ 0 621,366 (383,583)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock-based compensation expense 7,862   7,862  
Common stock issued upon exercise of stock options (in shares)   1,374    
Common stock issued upon exercise of stock options 22   22  
Common stock issued under the 2023 Employee Stock Purchase Plan (in shares)   3,815    
Common stock issued under the 2023 Employee Stock Purchase Plan 67   67  
Issuance of common stock in at-the-market offering, net of offering costs (in shares)   209,529    
Issuance of common stock in at-the-market offering, net of offering costs 5,904   5,904  
Deferred costs related to offering (17)   (17)  
Net loss $ (34,488)     (34,488)
Ending balance (in shares) at Jun. 30, 2026 15,830,504 15,830,504    
Ending balance at Jun. 30, 2026 $ 217,133 $ 0 $ 635,204 $ (418,071)